On October 28, 2024, Merck and Moderna, Inc. announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial. This trial evaluates V940 (mRNA-4157), an investigational individualized neoantigen therapy, in combination with KEYTRUDA (pembrolizumab).
The study focuses on adjuvant treatment for patients with resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC) who did not achieve a pathological complete response after neoadjuvant Keytruda and chemotherapy.
This collaboration represents a significant step in advancing personalized cancer therapies. The progression of V940 into late-stage development underscores Merck's strategy to innovate beyond its current oncology portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.